

SUPPLEMENTARY DATA

Supplementary Table 1. Insulin Antibodies (%B/T)

Week		IDeg(A)	IDeg(B)
Cross-reacting antibodies (%B/T)			
0	n	57	60
	Median (min-max)	4.5 (0 – 68.3)	4.5 (-0.1 – 53.7)
18	n	55	59
	Median (min-max)	8.5 (0.6 – 70.8)	6.1 (0 – 72.1)
IDeg-specific antibodies (%B/T)			
0	n	59	60
	Median (min-max)	-0.2 (-1.0 – 5.8)	-0.2 (-2.0 – 1.5)
18	n	55	60
	Median (min-max)	-0.2 (-1.9 – 2.4)	-0.2 (-1.4 – 1.7)
IAsp-specific antibodies (%B/T)			
0	n	58	60
	Median (min-max)	0.7 (-0.1 – 14.6)	0.9 (-0.8 – 17.8)
18	n	55	60
	Median (min-max)	0.9 (-0.2 – 14.3)	0.7 (-0.5 – 17.4)

n: number of subjects; %B/T: percent bound over total; IGLar-specific antibodies were not measured in this trial.

Supplementary Table 2. List of Principle Investigators

Country	Principle Investigators
Australia	Tony Roberts, Andrew Lowy, Robert Moses, Geoff Nicholson and Murray Gerstman
Germany	Ulrich Wendisch, Alexander Segner, Gerhard Klausmann, Stephan Maxeiner, Karsten Milek and Andrea Mölle
Norway	Kåre I. Birkeland, Svein Skeie, Sverre Madsbu, Stefnir Gudnason, Marianne Astor and Mikkel Høiberg
Sweden	Johan Jendle, Per-Eric Lins, Mona Landin-Olsson, Peter Fors and Ann-Sofie Bolmér
United States	Robert Ratner, Ronald Brazg, David Fitz-Patrick, Gregory Peterson, Michael Reeves, and Julio Rosenstock

SUPPLEMENTARY DATA

Supplementary Figure 1: Mean 9-point SMPG Profiles at baseline (Panel A) and after 16 weeks of treatment (Panel B).

